Eltrombopag in Pediatric Severe Aplastic Anemia: Favorable Outcomes
Blood Journals Portfolio shared a post on X:
”Eltrombopag’s pharmacokinetics profile was similar to that seen in patients with immune thrombocytopenia, with no unexpected safety signals.”
Read the full article here.
Title: Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Authors: Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Sujith Samarasinghe, Jason E. Farrar, Chi-kong Li, Nongnuch Sirachainan, Bunchoo Pongtanakul, Patcharee Komvilaisak, Ludmila Zubarovskaya, Jennifer A. Rothman, Kelly Walkovich, Taizo A. Nakano, Alison A. Bertuch, Anabela Ferrao, Rukhmi Bhat, Rabi Hanna, Kathleen Overholt, Jessica Boklan, Tze Fang Wong, Qinxia Wang, Patrick Urban, Brigitte Strahm, Winfred Wang, Adrianna Vlachos, David A. Williams
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis